MetaCap

Eledon Pharmaceuticals (ELDN) vs InflaRx N.V. (IFRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eledon Pharmaceuticals (ELDN) has outperformed InflaRx N.V. (IFRX) over the past year, gaining 23.6% versus a loss of 11.9%. Over five years, ELDN leads with a -65.6% price change compared with -79.5% for IFRX. InflaRx N.V. is the larger company by market cap ($153.3 million vs $150.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELDN+23.61%IFRX-11.86%
+203%+81%-41%
Nov 21, 20251 yearNov 20, 2026
ELDN-66.48%IFRX-78.15%
+21%-34%-89%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELDN versus IFRX key metrics
MetricELDNIFRX
Share price$1.78$1.04
Market cap$150.34M$153.26M
1-day change-6.32%-4.59%
YTD return+17.88%+2.97%
1-year return+23.61%-11.86%
5-year return-65.64%-79.53%
EPS (TTM)$-0.73$-0.37
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-45.62M—
52-week high$4.49$2.95
52-week low$1.39$0.798
Distance from 52-week high-60.36%-64.73%
Analyst consensusstrong_buynone
Avg. price target upside+405.62%+696.15%
Average volume931.77K868.66K
Shares outstanding84.46M147.37M
Employees3365
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELDN has outperformed IFRX by 35.5 percentage points over the past year.

About Eledon Pharmaceuticals

ELDN stock →

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About InflaRx N.V.

IFRX stock →

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

ELDN vs IFRX FAQ

Which is bigger, Eledon Pharmaceuticals or InflaRx N.V.?

InflaRx N.V. (IFRX) is larger, with a market capitalization of $153.26M compared with $150.34M for Eledon Pharmaceuticals (ELDN).

Which stock has performed better over the past year, ELDN or IFRX?

ELDN returned +23.61% over the past 12 months, compared with -11.86% for IFRX (price return, excluding dividends). Past performance does not predict future results.

Are Eledon Pharmaceuticals and InflaRx N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons